Reports say Eli Lilly’s experimental weight-loss drug retatrutide reduces symptoms of sleep apnea. New York Post reports that in a trial, the drug eased sleep apnea symptoms by more than 50% in 68% of participants.
Fox News adds context that the treatment also helps with nighttime sleep disruptions linked to breathing interruptions, and it highlights additional outcomes beyond sleep. It says retatrutide contributes to significant weight loss in sleep apnea patients and points to cardiovascular benefits mentioned in the report.
Taken together, the outlets frame the study around two connected effects: improvement in sleep apnea–related breathing problems and weight reduction, with Fox News also emphasizing potential heart-related advantages. The coverage focuses on early trial findings and centers on retatrutide’s role in addressing nighttime disruptions that can affect millions.
